Published in Clin Trials on October 08, 2010
Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials. J Clin Oncol (2013) 1.30
A product of independent beta probabilities dose escalation design for dual-agent phase I trials. Stat Med (2015) 1.05
A phase I/II seamless dose escalation/expansion with adaptive randomization scheme (SEARS). Clin Trials (2013) 0.95
Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents. J Biopharm Stat (2014) 0.87
Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering. Stat Med (2014) 0.79
Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials. Clin Cancer Res (2016) 0.79
A novel Bayesian seamless phase I/II design. PLoS One (2013) 0.78
Approaches to modernize the combination drug development paradigm. Genome Med (2016) 0.77
The rapid enrollment design for Phase I clinical trials. Stat Med (2016) 0.77
Performance of toxicity probability interval based designs in contrast to the continual reassessment method. Stat Med (2016) 0.75
Practical designs for Phase I combination studies in oncology. J Biopharm Stat (2016) 0.75
TEAMS: Toxicity- and Efficacy-based Dose Insertion Design with Adaptive Model Selection for Phase I/II Dose-Escalation Trials in Oncology. Stat Biosci (2015) 0.75
The continual reassessment method for multiple toxicity grades: a bayesian model selection approach. PLoS One (2014) 0.75
A Novel Non-Antibiotic Nitroglycerin Based Catheter Lock Solution for the Prevention of Intraluminal Central Venous Catheter Infections in Cancer Patients. Antimicrob Agents Chemother (2017) 0.75
Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics (1990) 10.19
Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics (2000) 5.50
Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med (1998) 4.19
Some practical improvements in the continual reassessment method for phase I studies. Stat Med (1995) 3.43
Model calibration in the continual reassessment method. Clin Trials (2009) 2.75
Practical implementation of a modified continual reassessment method for dose-finding trials. Cancer Chemother Pharmacol (1998) 2.35
The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach. Biometrics (2007) 2.07
A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies. Clin Trials (2008) 2.06
Dose-finding in phase I clinical trials based on toxicity probability intervals. Clin Trials (2007) 1.85
The continual reassessment method for dose-finding studies: a tutorial. Clin Trials (2006) 1.79
Practical model-based dose-finding in phase I clinical trials: methods based on toxicity. Int J Gynecol Cancer (2003) 1.58
Dose finding using the biased coin up-and-down design and isotonic regression. Biometrics (2002) 1.50
Sensitivity of dose-finding studies to observation errors. Contemp Clin Trials (2009) 0.96
Epidermal electronics. Science (2011) 8.65
Regions of strong coupling between soil moisture and precipitation. Science (2004) 5.96
Single-cell RNA-Seq profiling of human preimplantation embryos and embryonic stem cells. Nat Struct Mol Biol (2013) 4.04
Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer (2004) 3.83
Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci U S A (2008) 3.71
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol (2010) 2.58
Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer (2006) 2.30
Prognostic factors for survival in melanoma patients with brain metastases. Cancer (2010) 2.23
Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst (2007) 2.23
Amphipathic helix-dependent localization of NS5A mediates hepatitis C virus RNA replication. J Virol (2003) 2.20
Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys (2011) 2.18
EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res (2005) 2.17
Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res (2010) 2.14
An orthotopic nude mouse model of oral tongue squamous cell carcinoma. Clin Cancer Res (2002) 2.11
The effect of tobacco outlet density and proximity on smoking cessation. Am J Public Health (2010) 2.04
Applications of beta-mixture models in bioinformatics. Bioinformatics (2005) 2.04
An N-terminal amphipathic helix in hepatitis C virus (HCV) NS4B mediates membrane association, correct localization of replication complex proteins, and HCV RNA replication. J Virol (2004) 1.99
Alcohol consumption and visual impairment in a rural Northern Chinese population. Ophthalmic Epidemiol (2014) 1.98
Low-level smoking among Spanish-speaking Latino smokers: relationships with demographics, tobacco dependence, withdrawal, and cessation. Nicotine Tob Res (2009) 1.96
Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios. Biometrics (2006) 1.95
A functional genetic variant in microRNA-196a2 is associated with increased susceptibility of lung cancer in Chinese. Cancer Epidemiol Biomarkers Prev (2009) 1.93
Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial. Lancet Oncol (2012) 1.90
Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol (2009) 1.88
Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood (2009) 1.86
Essential role for protein kinase D family kinases in the regulation of class II histone deacetylases in B lymphocytes. Mol Cell Biol (2006) 1.85
Dose-finding in phase I clinical trials based on toxicity probability intervals. Clin Trials (2007) 1.85
Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study. Eur Urol (2013) 1.81
Mechanisms linking socioeconomic status to smoking cessation: a structural equation modeling approach. Health Psychol (2010) 1.81
Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell Proteomics (2011) 1.81
Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2010) 1.79
Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One (2010) 1.78
VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol (2008) 1.77
miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer (2010) 1.76
Borrowing strength with nonexchangeable priors over subpopulations. Biometrics (2011) 1.75
MicroRNA-181a sensitizes human malignant glioma U87MG cells to radiation by targeting Bcl-2. Oncol Rep (2010) 1.74
[18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci U S A (2007) 1.73
Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol (2010) 1.70
MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol (2009) 1.69
Novel CACNA1S mutation causes autosomal dominant hypokalemic periodic paralysis in a Chinese family. J Mol Med (Berl) (2005) 1.63
Flavivirus activation of plasmacytoid dendritic cells delineates key elements of TLR7 signaling beyond endosomal recognition. J Immunol (2006) 1.61
Subjective social status affects smoking abstinence during acute withdrawal through affective mediators. Addiction (2010) 1.60
Decision analysis for prophylactic cranial irradiation for patients with small-cell lung cancer. J Clin Oncol (2006) 1.57
Financial strain and smoking cessation among racially/ethnically diverse smokers. Am J Public Health (2010) 1.57
Oxygen reduction on well-defined core-shell nanocatalysts: particle size, facet, and Pt shell thickness effects. J Am Chem Soc (2009) 1.55
Malignant transformation of testicular teratoma: a chemoresistant phenotype. Urol Oncol (2008) 1.54
An integrated high-throughput data acquisition system for biological solution X-ray scattering studies. J Synchrotron Radiat (2012) 1.52
Genetic variation of PSCA gene is associated with the risk of both diffuse- and intestinal-type gastric cancer in a Chinese population. Int J Cancer (2010) 1.49
Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression? Cancer (2007) 1.49
Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experience. J Urol (2007) 1.49
Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Clin Cancer Res (2009) 1.48
miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol (2011) 1.48
Reaching and treating Spanish-speaking smokers through the National Cancer Institute's Cancer Information Service. A randomized controlled trial. Cancer (2007) 1.47
Correlation between annual volume of cystectomy, professional staffing, and outcomes: a statewide, population-based study. Cancer (2005) 1.47
A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression. Br J Haematol (2003) 1.47
miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis (2012) 1.45
Neurocognitive function before and after surgery for insular gliomas. J Neurosurg (2011) 1.44
A simple automated stimulator of mechanically induced arrhythmias in the isolated rat heart. Exp Physiol (2009) 1.44
Modified suprapubic prostatectomy without irrigation is safe. Urology (2009) 1.43
Three-dimensional reconstruction of the uterine vascular supply through vascular casting and thin slice computed tomography scanning. Minim Invasive Ther Allied Technol (2009) 1.42
Activating enhancer-binding protein-2β nucleolar localization predicts poor survival after stage I non-small cell lung cancer resection. Ann Thorac Surg (2011) 1.41
New understanding of hardening mechanism of TiN/SiNx-based nanocomposite films. Nanoscale Res Lett (2013) 1.39
Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. Clin Cancer Res (2012) 1.39
miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol (2011) 1.39
Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol (2014) 1.38
Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. Epigenetics (2010) 1.37
C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci U S A (2011) 1.36
Resveratrol protects human lens epithelial cells against H2O2-induced oxidative stress by increasing catalase, SOD-1, and HO-1 expression. Mol Vis (2010) 1.35
Associations of mindfulness with nicotine dependence, withdrawal, and agency. Subst Abus (2009) 1.35
Core-protected platinum monolayer shell high-stability electrocatalysts for fuel-cell cathodes. Angew Chem Int Ed Engl (2010) 1.34
Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Mod Pathol (2009) 1.34
In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J Clin Invest (2003) 1.33
Chemotherapy improves the survival of patients with choroid plexus carcinoma: a meta-analysis of individual cases with choroid plexus tumors. J Neurooncol (2007) 1.33
Chitosan modification and pharmaceutical/biomedical applications. Mar Drugs (2010) 1.33
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. Cancer (2012) 1.32
Dose--schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation. Stat Med (2008) 1.32
Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res (2009) 1.32
A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci U S A (2009) 1.32
An investigation of the self-assembly of neutral, interlaced, triple-stranded molecular braids. Chemistry (2006) 1.31
Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. Brain Behav Immun (2012) 1.31
Advance in chitosan hydrolysis by non-specific cellulases. Bioresour Technol (2008) 1.31
Kupffer cells are associated with apoptosis, inflammation and fibrotic effects in hepatic fibrosis in rats. Lab Invest (2010) 1.29
Sorafenib inhibits transforming growth factor β1-mediated epithelial-mesenchymal transition and apoptosis in mouse hepatocytes. Hepatology (2011) 1.28
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood (2004) 1.28
Preventing postpartum smoking relapse among diverse low-income women: a randomized clinical trial. Nicotine Tob Res (2010) 1.27
Psychometric evaluation of the Chinese (mainland) version of Job Content Questionnaire: a study in university hospitals. Ind Health (2004) 1.26
Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J Clin Oncol (2004) 1.25
Self-assembly of an interlaced triple-stranded molecular braid with an unprecedented topology through hydrogen-bonding interactions. Angew Chem Int Ed Engl (2005) 1.25
Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin. Cancer Res (2007) 1.25
Hydrogen sulfide contributes to cardioprotection during ischemia-reperfusion injury by opening K ATP channels. Can J Physiol Pharmacol (2007) 1.25
Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer. Clin Cancer Res (2008) 1.24
Contribution of sulfur-containing compounds to the colour-inhibiting effect and improved antioxidant activity of Maillard reaction products of soybean protein hydrolysates. J Sci Food Agric (2010) 1.24
Race/ethnicity and multiple cancer risk factors among individuals seeking smoking cessation treatment. Cancer Epidemiol Biomarkers Prev (2008) 1.23
High-performance semiconducting polythiophenes for organic thin-film transistors. J Am Chem Soc (2004) 1.23
A method for noninvasive detection of fetal large deletions/duplications by low coverage massively parallel sequencing. Prenat Diagn (2013) 1.22
Overexpression of vimentin contributes to prostate cancer invasion and metastasis via src regulation. Anticancer Res (2008) 1.21
Ezrin silencing by small hairpin RNA reverses metastatic behaviors of human breast cancer cells. Cancer Lett (2007) 1.20
Comprehensive assessment of quality of life and psychosocial adjustment in patients with renal tumors undergoing open, laparoscopic and nephron sparing surgery. J Urol (2012) 1.19
Effects of Fuzheng Huayu 319 recipe on liver fibrosis in chronic hepatitis B. World J Gastroenterol (1998) 1.19
Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin Cancer Res (2006) 1.18